Pure Global AI
NCT06239454Recruiting

Interleaving Stimulation Improves Dyskinesia in Parkinson's Disease

Interleaving Stimulation Improves Dyskinesia in Parkinson's Disease: Randomized, Double-blind, Controlled Trial
Huashan HospitalClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Parkinson's Disease
Drug/Device/Intervention
interleaving stimulation
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Huashan Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2022
End date
Feb 28, 2025
Enrollment
50 participants
Primary outcome

dyskinesia scores (United Parkinson's Disease Rating Scale Part IV, item 32 + item 33),Parkinson's disease quality of life-39 (PDQ-39) scores

Summary

This study is designed as a prospective, randomized, double-blind, controlled study to assess
 putative differences in the effect of interleaving stimulation and empirical stimulation with
 regards to post-operation dyskinesia control. The primary objective is to assess putative
 differences in the effect of interleaving stimulation and empirical stimulation with regards
 to dyskinesia control.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismPostencephalitic parkinsonism
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06239454
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06239454 through Pure Global AI's free database. This phase not specified trial is sponsored by Huashan Hospital and is currently Recruiting. The study focuses on Parkinson's Disease. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.